Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07353957 | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | PHASE2 | RECRUITING | 180 | — | — | Mar 27, 2025 | Feb 27, 2031 | Jun 5, 2026 | 24 | United States, Australia +5 |
ORR was defined as the proportion of participants who had a complete response (CR) or partial response (PR) per RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| First line squamous non-small cell lung cancer patients | EXPERIMENTAL | - |
| First line non-squamous non-small cell lung cancer patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Petosemtamab + Pembrolizumab | COMBINATION_PRODUCT | Petosemtamab + Pembrolizumab |
Inclusion Criteria: * Able to provide written informed consent and is willing and able to comply with all study procedures and contraception requirements * Age ≥ 18 years at the signing of ICF * At least 1 measurable lesion as defined by RECIST 1.1 * ECOG performance status of 0 or 1 * Life expecta...